Published in Gene Therapy Weekly, September 11th, 2003
"It has previously been established that a single systemic administration of retroviral vector containing angiotensin 11 type I receptor antisense (AT(1)R-AS) in the neonatal spontaneously hypertensive rat (SHR) prevents development of hypertension, and in addition cardiac hypertrophy and endothelial dysfunction," researchers in the United States explained. "However, these studies could not determine whether the effects of AT(1)R-AS on high blood pressure (BP) and endothelial function were independent."
"Angiotensin receptor blockers have...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.